Medical Hypotheses 84 (2015) 601
Contents lists available at ScienceDirect
Medical Hypotheses journal homepage: www.elsevier.com/locate/mehy
Correspondence Helicobacter pylori, Oxalobacter formigenes, and risk of kidney stonesq
To the Editor, Verit and Güner propose that Helicobacter pylori might have a role in promoting kidney stone formation [1]. While their paper is interesting, they neglect to cite our work demonstrating that treatment of H. pylori is associated with reduction in colonization with Oxalobacter formigenes [2]. O. formigenes is an organism that has been associated with a reduced rate of kidney stones [3]. We therefore proposed that since O. formigenes is sensitive to the antibiotics commonly used to eliminate colonization with H. pylori, the practice of administering antibiotics for H. pylori could be a risk factor for stone formation. We note that consistent with our hypothesis, but not with that of Verit and Güner, most data suggest that worldwide prevalence of kidney stones is increasing [4, 5], while the prevalence of H. pylori is decreasing [6]. Conflict of interest None declared. References [1] Verit A, Guner ND. Helicobacter pylori and urinary system stones: Endoluminal damage as sub-hypothesis to support the current stone theory. Med Hypotheses 2014;83(6):677–80.
q The author is supported by the Rare Kidney Stone Consortium (U54KD083908), which is a part of the NIH Rare Diseases Clinical Research Network, supported through collaboration between the NIH Office of Rare Diseases Research at the National Center for Advancing Translational Sciences and National Institute of Diabetes and Digestive and Kidney Disease.
http://dx.doi.org/10.1016/j.mehy.2015.03.005 0306-9877/Published by Elsevier Ltd.
[2] Kharlamb V, Schelker J, Francois F, Jiang J, Holmes RP, Goldfarb DS. Oral antibiotic treatment of Helicobacter pylori leads to persistently reduced intestinal colonization rates with Oxalobacter formigenes. J Endourol 2011;25(11):1781–5. [3] Kaufman DW, Kelly JP, Curhan GC, Anderson TE, Dretler SP, Preminger GM, et al. Oxalobacter formigenes may reduce the risk of calcium oxalate kidney stones. J Am Soc Nephrol 2008;19(6):1197–203. [4] Scales CD, Smith AC, Hanley JM, Saigal CS. Prevalence of kidney stones in the United States. Eur Urol 2012;62(1):160–5. [5] Romero V, Akpinar H, Assimos DG. Kidney stones: a global picture of prevalence, incidence, and associated risk factors. Rev Urol 2010;12(2– 3):e86–96. [6] Blaser MJ, Falkow S. What are the consequences of the disappearing human microbiota? Nat Rev Microbiol 2009;7(12):887–94.
⇑
David S. Goldfarb Division of Nephrology, New York University Medical Center, USA Medicine and Physiology, NYU School of Medicine, USA ⇑ Address: Nephrology Section, NYVAMC, 423 E. 23rd St., New York, NY 10010, USA. Tel.: +1 (212) 263 0744; fax: +1 (212) 951 6842. E-mail address: [email protected]
Contents lists available at ScienceDirect
Medical Hypotheses journal homepage: www.elsevier.com/locate/mehy
Correspondence Helicobacter pylori, Oxalobacter formigenes, and risk of kidney stonesq
To the Editor, Verit and Güner propose that Helicobacter pylori might have a role in promoting kidney stone formation [1]. While their paper is interesting, they neglect to cite our work demonstrating that treatment of H. pylori is associated with reduction in colonization with Oxalobacter formigenes [2]. O. formigenes is an organism that has been associated with a reduced rate of kidney stones [3]. We therefore proposed that since O. formigenes is sensitive to the antibiotics commonly used to eliminate colonization with H. pylori, the practice of administering antibiotics for H. pylori could be a risk factor for stone formation. We note that consistent with our hypothesis, but not with that of Verit and Güner, most data suggest that worldwide prevalence of kidney stones is increasing [4, 5], while the prevalence of H. pylori is decreasing [6]. Conflict of interest None declared. References [1] Verit A, Guner ND. Helicobacter pylori and urinary system stones: Endoluminal damage as sub-hypothesis to support the current stone theory. Med Hypotheses 2014;83(6):677–80.
q The author is supported by the Rare Kidney Stone Consortium (U54KD083908), which is a part of the NIH Rare Diseases Clinical Research Network, supported through collaboration between the NIH Office of Rare Diseases Research at the National Center for Advancing Translational Sciences and National Institute of Diabetes and Digestive and Kidney Disease.
http://dx.doi.org/10.1016/j.mehy.2015.03.005 0306-9877/Published by Elsevier Ltd.
[2] Kharlamb V, Schelker J, Francois F, Jiang J, Holmes RP, Goldfarb DS. Oral antibiotic treatment of Helicobacter pylori leads to persistently reduced intestinal colonization rates with Oxalobacter formigenes. J Endourol 2011;25(11):1781–5. [3] Kaufman DW, Kelly JP, Curhan GC, Anderson TE, Dretler SP, Preminger GM, et al. Oxalobacter formigenes may reduce the risk of calcium oxalate kidney stones. J Am Soc Nephrol 2008;19(6):1197–203. [4] Scales CD, Smith AC, Hanley JM, Saigal CS. Prevalence of kidney stones in the United States. Eur Urol 2012;62(1):160–5. [5] Romero V, Akpinar H, Assimos DG. Kidney stones: a global picture of prevalence, incidence, and associated risk factors. Rev Urol 2010;12(2– 3):e86–96. [6] Blaser MJ, Falkow S. What are the consequences of the disappearing human microbiota? Nat Rev Microbiol 2009;7(12):887–94.
⇑
David S. Goldfarb Division of Nephrology, New York University Medical Center, USA Medicine and Physiology, NYU School of Medicine, USA ⇑ Address: Nephrology Section, NYVAMC, 423 E. 23rd St., New York, NY 10010, USA. Tel.: +1 (212) 263 0744; fax: +1 (212) 951 6842. E-mail address: [email protected]
